Company Overview
About Nephrogen
Nephrogen is a San Francisco-based preclinical gene therapy company — backed by Y Combinator (W20) with $1.1 million in total funding including $775,000 raised to date plus a $325,000 NIH SBIR grant, and currently raising a $4 million seed round with support from StartX and 2048 Ventures — developing curative gene therapies for kidney diseases, with polycystic kidney disease (PKD) as the lead program targeting the 600,000 Americans with the autosomal dominant PKD subtype, an inherited kidney cyst disorder with no disease-modifying treatments that currently progresses to end-stage renal disease requiring dialysis or transplant in the majority of patients. Founded by researchers with combined expertise in AI-driven drug discovery, genetic engineering, and nephrology, Nephrogen applies AI target identification and gene therapy delivery to the largest category of rare inherited kidney diseases.
Business Model & Competitive Advantage
Nephrogen's gene therapy approach to PKD addresses the root cause rather than managing progression: PKD is caused by mutations in the PKD1 or PKD2 genes that disrupt polycystin protein function in kidney tubule cells — causing abnormal fluid-filled cyst growth that progressively replaces normal kidney tissue over decades. Existing therapies (tolvaptan, the only FDA-approved treatment) slow but do not halt PKD progression and carry liver toxicity risks requiring regular monitoring. Nephrogen's gene therapy program uses viral vectors to deliver functional copies of the mutated gene or gene-silencing constructs to kidney cells — targeting the molecular defect rather than downstream cyst growth pathways. The AI drug discovery integration (computational models identifying optimal delivery vectors, expression cassette designs, and dosing regimens from preclinical data) accelerates the iterative optimization that gene therapy development requires. The NIH SBIR grant (Phase I research funding from the National Institute of Diabetes and Digestive and Kidney Diseases) validates the scientific merit of Nephrogen's approach.
Competitive Landscape 2025–2026
In 2025, Nephrogen competes in the gene therapy, rare kidney disease, and genetic medicine market with Passage Bio (rare neurological gene therapy, $216M raised), CRISPR Therapeutics (NASDAQ: CRSP, gene editing, multiple programs), and Oricell Therapeutics (kidney-focused gene therapy) for preclinical PKD gene therapy program development and seed investment in genetic kidney disease. The PKD Foundation estimates 600,000 Americans and 12.5 million people worldwide have ADPKD — making it one of the most common inherited kidney diseases with a large patient population relative to other rare disease targets. Nephrogen's $4 million seed raise target reflects the preclinical stage milestone funding needed to generate the in vivo efficacy and safety data required for IND-enabling studies. The 2025 strategy focuses on demonstrating proof-of-concept gene therapy efficacy in PKD mouse models, building the delivery platform for kidney-targeted gene therapy vectors, and establishing the manufacturing process development foundation.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Nephrogen is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Not So Random Others
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
Chick-fil-A
Chick-fil-A is the largest US quick-service chicken restaurant chain, generating over $22 billion in annual system-wide sales from approximately 3,000 locations — more revenue per restaurant than any
Yoneda Labs
Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists wit
Hey Telo
Hey Telo is a Berlin-based AI voice agent company building phone-answering and administrative automation specifically for Germany's 1 million+ independent craftsman businesses (Handwerksbetriebe) — HV
H&M (Hennes & Mauritz)
H&M Hennes & Mauritz is a Swedish multinational fashion retailer founded in 1947, operating brands including H&M, COS, & Other Stories, ARKET, and Weekday. The company runs approximately 4,100 stores
Compare Nephrogen with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Nephrogen? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Nephrogen Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Nephrogen vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →